MX2009008408A - Diagnosis y tratamiento de preeclampsia. - Google Patents

Diagnosis y tratamiento de preeclampsia.

Info

Publication number
MX2009008408A
MX2009008408A MX2009008408A MX2009008408A MX2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A MX 2009008408 A MX2009008408 A MX 2009008408A
Authority
MX
Mexico
Prior art keywords
preeclampsia
diagnosis
relates
treatment
disease
Prior art date
Application number
MX2009008408A
Other languages
English (en)
Inventor
Stefan Hansson
Bo Aakerstroem
Original Assignee
Stefan Hansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Hansson filed Critical Stefan Hansson
Publication of MX2009008408A publication Critical patent/MX2009008408A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere a biomarcadores para preeclampsia así como tratamientos de esta enfermedad. En particular, la invención se refiere a métodos para diagnosis o ayuda en la diagnosis de preeclampsia de un mamífero hembra preñado para detectar niveles elevados de hemoglobina libre, particularmente hemoglobina fetal libre. Esto facilita y hace posible la diagnosis temprana y la intervención clínica temprana cuando se encuentra una condición preeclámptica. Además, la invención se refiere a un método para tratar mamíferos hembra con preeclampsia con el propósito de invertir las condiciones patológicas asociadas con esta enfermedad.
MX2009008408A 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia. MX2009008408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
MX2009008408A true MX2009008408A (es) 2009-11-02

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013001577A MX347788B (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.
MX2009008408A MX2009008408A (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013001577A MX347788B (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Country Status (18)

Country Link
US (3) US8568999B2 (es)
EP (3) EP2613150A1 (es)
JP (2) JP5604111B2 (es)
KR (2) KR101608501B1 (es)
AU (1) AU2008214837B2 (es)
BR (1) BRPI0808340A2 (es)
CA (1) CA2674204C (es)
DK (2) DK2111555T3 (es)
EA (2) EA022609B1 (es)
ES (2) ES2426069T3 (es)
HR (2) HRP20130809T1 (es)
HU (1) HUE031613T2 (es)
MX (2) MX347788B (es)
NZ (1) NZ578077A (es)
PL (2) PL2614832T3 (es)
PT (2) PT2111555E (es)
WO (1) WO2008098734A1 (es)
ZA (1) ZA200905101B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031613T2 (en) 2007-02-12 2017-09-28 A1M Pharma Ab Diagnosis and treatment of preeclampsia
DK2313106T3 (en) * 2008-07-18 2016-07-25 A1M Pharma Ab MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
JP5926722B2 (ja) 2010-03-24 2016-05-25 プリールミナ ダイアグノスティックス エービーＰｒｅｅｌｕｍｉｎａ Ｄｉａｇｎｏｓｔｉｃｓ Ａｂ 子癇前症の初期段階マーカーとしてのＨｂＦおよびＡ１Ｍ
KR101858765B1 (ko) * 2010-03-31 2018-05-16 세키스이 메디칼 가부시키가이샤 면역 크로마토그래피를 이용한 측정 방법, 면역 크로마토그래피용 테스트 스트립 및 면역 크로마토그래피용 측정 시약 키트
EP2766726A1 (en) 2011-10-14 2014-08-20 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
WO2014037390A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
EP3271727A1 (en) 2015-03-16 2018-01-24 A1M Pharma AB Biomarkers for preeclampsia
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
CN109072479A (zh) 2015-12-04 2018-12-21 Nx产前公司 使用循环微粒对自发性早产风险进行分层
EP4317959A3 (en) * 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
EP1423706B1 (en) 2001-09-04 2007-04-18 IQ Corporation B.V. Determination and quantification of red blood cell populations in samples
CN1522369A (zh) * 2002-03-29 2004-08-18 ���µ�����ҵ��ʽ���� 血液处理方法及其装置、血红蛋白类测定方法及其装置
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
CA2525236C (en) * 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
JP2007513884A (ja) * 2003-11-26 2007-05-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高められた心血管性リスクのインジケーターとしての尿細管性蛋白尿
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
CA2636353A1 (en) * 2006-01-18 2007-07-26 Georg Wick Test systems for the analysis of polypeptides and cells adhering to silicones
HUE031613T2 (en) 2007-02-12 2017-09-28 A1M Pharma Ab Diagnosis and treatment of preeclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
DK2313106T3 (en) 2008-07-18 2016-07-25 A1M Pharma Ab MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin
JP5926722B2 (ja) 2010-03-24 2016-05-25 プリールミナ ダイアグノスティックス エービーＰｒｅｅｌｕｍｉｎａ Ｄｉａｇｎｏｓｔｉｃｓ Ａｂ 子癇前症の初期段階マーカーとしてのＨｂＦおよびＡ１Ｍ

Also Published As

Publication number Publication date
EP2614832A1 (en) 2013-07-17
CA2674204C (en) 2017-07-11
JP2014012670A (ja) 2014-01-23
KR101608501B1 (ko) 2016-04-04
EA200970758A1 (ru) 2010-02-26
HRP20161266T1 (hr) 2016-12-16
MX347788B (es) 2017-05-12
PT2614832T (pt) 2016-10-18
DK2111555T3 (da) 2013-09-02
EA022609B1 (ru) 2016-02-29
US8568999B2 (en) 2013-10-29
AU2008214837B2 (en) 2013-01-10
KR20100015315A (ko) 2010-02-12
AU2008214837A1 (en) 2008-08-21
EP2111555A1 (en) 2009-10-28
US20140065170A1 (en) 2014-03-06
US20180284087A1 (en) 2018-10-04
HRP20130809T1 (en) 2013-10-11
ES2426069T3 (es) 2013-10-21
EP2614832B1 (en) 2016-07-13
KR101454013B1 (ko) 2014-11-12
PL2111555T3 (pl) 2013-10-31
NZ578077A (en) 2012-04-27
CA2674204A1 (en) 2008-08-21
EP2111555B1 (en) 2013-05-29
US20100105070A1 (en) 2010-04-29
DK2614832T3 (da) 2016-10-31
JP2010518386A (ja) 2010-05-27
BRPI0808340A2 (pt) 2017-05-30
PT2111555E (pt) 2013-09-04
JP5604111B2 (ja) 2014-10-08
KR20140095572A (ko) 2014-08-01
WO2008098734A1 (en) 2008-08-21
EP2613150A1 (en) 2013-07-10
HUE031613T2 (en) 2017-09-28
ZA200905101B (en) 2012-01-25
US10359406B2 (en) 2019-07-23
ES2599003T3 (es) 2017-01-31
PL2614832T3 (pl) 2017-01-31
EA201500335A1 (ru) 2016-08-31
JP5792772B2 (ja) 2015-10-14
EA031877B1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
MX347788B (es) Diagnosis y tratamiento de preeclampsia.
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
EA201290716A1 (ru) Способы и композиции для неинвазивной пренатальной диагностики анеуплоидии плода
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2013022995A3 (en) Biomarker compositions and methods
WO2013134786A3 (en) Biomarker compositions and methods
EP2557425A3 (en) Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
WO2010091049A3 (en) Diagnosis and treatment of cancer
TW200730138A (en) Image analysis methods for gleno-humeral joint morphology
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2010090834A3 (en) Netrin-1 as a biomarker of injury and disease
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2006026557A3 (en) Methods and kits for predicting risk for peterm labor
WO2007041283A3 (en) Maternal chelation for embryo, fetal, and infant benefit
PH12017500051A1 (en) Nutritional composition for use to treat or prevent pregnancy related conditions
WO2007109293A3 (en) Early diagnosis of congenital abnormalities in the offspring of diabetic mothers
UA51718U (ru) Способ отбора беременных женщин с рубцом на матке для попытки влагалищных родов с определением статуса кандидата на дородовом и интранатальном этапах
WO2013001293A3 (en) Diagnostic method for downs syndrome
RU2006129738A (ru) Способ прогнозирования восстановления эффективного деторождения после иммуноцитотерапии у женщин с невынашиванием беременности ранних сроков
WO2007044438A3 (en) Diagnosis and prevention of fetal heart disease
MD218Z (ro) Metodă de diagnosticare a tipului patternului neuropsihologic în afecţiunile cerebelare
UA56043U (ru) Способ прогнозирования состояния больного мочекаменной болезнью, имеющего нефростому
Jayasinghe Glucose challenge test as a screening for gestational diabetes mellitus and the influence of some of the associated risk factors

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights